The National Cancer Research Institute (NCRI) is pleased to announce that the charity Pancreatic Cancer UK has recently joined as a Partner. NCRI has already welcomed two new Partners this year, Prostate Cancer Research Centre and Cancer Research Wales.
NCRI’s 20 Partners include cancer research charities and funding bodies, representing all four nations of the United Kingdom. NCRI Partners work together to coordinate their research, and in doing so aim to avoid unnecessary duplication and maximise the impact of research for cancer patients and the public.
“Collaboration is essential if we are to continue to improve health and quality of life through cancer research, which is why I am delighted to announce our third new Partner of the year, Pancreatic Cancer UK.
Several of NCRI’s strategic priority areas, including early detection and diagnosis and living with and beyond cancer, are specifically relevant to pancreatic cancer. We look forward to working with Pancreatic Cancer UK to ensure coordination in pancreatic cancer research and translating this into maximum impact for patients.”
Iain Frame, CEO, NCRI
Pancreatic Cancer UK fund innovative research to change how we understand, diagnose and treat pancreatic cancer. By becoming NCRI Partners they will be able to work in partnership with some of the biggest and most influential cancer charities and funders in the world as well as a number of government bodies. It is a unique opportunity to learn and to collaborate in areas that affect all areas of cancer research, including early detection and diagnosis and living with and beyond cancer, which are particularly important for pancreatic cancer.
“For decades too little progress has been made in pancreatic cancer compared to other cancer types. Being a member of the NCRI allows us to work in partnership with some of the biggest and most influential cancer charities and funders in the world. It’s a unique opportunity to learn, to collaborate on key cross-cancer problems and to ensure that pancreatic cancer research is firmly on the agenda. Transforming early diagnosis for people with pancreatic cancer in the next three to four years is within our grasp. It’s exciting, and working with NCRI and learning from others can only help us make the progress that patients and their families so desperately need to see.”
Diana Jupp, CEO, Pancreatic Cancer UK